Trifluridine/tipiracil plus bevacizumab (FTD/TPI plus BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis.

被引：0
|
作者：
Yoshino, Takayuki
Taieb, Julien
Andre, Thierry
Kuboki, Yasutoshi
Pfeiffer, Per
Kumar, Amit
Hochster, Howard S.
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan
[2] Paris Descartes Univ, Hop Europ een Georges Pompidou, Paris, France
[3] Hop St Antoine, Paris, France
[4] Natl Canc Ctr Hosp East, Kashiwa, Japan
[5] Odense Univ Hosp, Odense, Denmark
[6] SmartAnalyst India Pvt Ltd, Gurugram, Haryan, India
[7] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3568
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer treatment
    Michel, Patryk S.
    Jankowski, Marek
    Sigorski, Dawid
    Kubiatowski, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (06):
  • [2] Real-world clinical outcomes of trifluridine-tipiracil monotherapy (FTD-TPI) and FTD-TPI plus bevacizumab combination therapy (FTD-TPI+bev) in 639 black patients (pts) with metastatic colorectal cancer (mCRC).
    Zhao, Ruizhi
    Khan, Nadeem
    Wang, Yuexi
    Pierre-Victor, Dudith
    Tepsick, Jon G.
    Sharath, R.
    Cann, Christopher G.
    Salimi, Tehseen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [3] Real-world clinical outcomes of patients (Pts) with metastatic colorectal cancer (mCRC) who received trifluridine-tipiracil (FTD-TPI) monotherapy or FTD-TPI plus bevacizumab (FTD-TPI plus bev) combination therapy.
    Nusrat, Maliha
    Zhao, Ruizhi
    Khan, Nadeem
    Wang, Yuexi
    Pierre-Victor, Dudith
    Tepsick, Jon G.
    Sharath, R.
    Cann, Christopher G.
    Salimi, Tehseen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 79 - 79
  • [4] Efficacy and safety of trifluridine/tipiracil and bevacizumab (FTD/TPI plus BEV) in patients with metastatic colorectal cancer (mCRC) in real-world practice.
    Lago, Nieves Martinez
    Reboredo, Margarita
    Gonzalez Gomez, Borja
    de Frutos Gonzalez, Belen
    Riesco Martinez, Maria Carmen
    Antonilli, Paula Carla
    Lopez Alfonso, Ana
    Gallardo Martin, Elena
    Fernandez Montes, Ana Fernandez
    Cabezon-Gutierrez, Luis
    Castineira, Antia Cousillas
    Ferreiro, Reyes
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 204 - 204
  • [5] Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer
    Victorino, Ana Paula Ornellas S.
    Meton, Fernando
    Mardegan, Luciana
    Festa, Juliana
    Piranda, Diogo N.
    Araujo, Kelly Borges
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (04)
  • [6] Real-world analysis of patient characteristics and outcomes among patients with metastatic colorectal cancer receiving trifluridine/tipiracil (FTD/TPI) plus bevacizumab versus FTD/TPI monotherapy.
    Hubbard, Joleen M.
    Lee, Lulu K.
    Grisolano, Jay L.
    Perkowski, Kacper
    Salimi, Tehseen
    Kazerooni, Reza
    Epstein, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 34 - 34
  • [7] Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014
    Yamazaki, K.
    Satake, H.
    Takashima, A.
    Mizusawa, J.
    Kataoka, T.
    Fukuda, H.
    Ishizuka, Y.
    Suwa, Y.
    Numata, K.
    Shibata, N.
    Asayama, M.
    Yokota, M.
    Tsushima, T.
    Ohta, T.
    Yamaguchi, T.
    Hamaguchi, T.
    Kanemitsu, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S738 - S738
  • [8] Frequency and management of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice
    Lago, N. Martinez
    Rendo, C. Reboredo
    Chucla, T. Calleja
    Salvador, M. Mateos
    Fernandez, F. Busto
    Gomez, J. de la Camara
    Reboredo-Lopez, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S100 - S101
  • [9] A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).
    Varghese, Anna M.
    Cardin, Dana Backlund
    Hersch, Jonathan
    Benson, Al Bowen
    Hochster, Howard S.
    Winkler, Robert E.
    Benedetti, Fabio
    Hamada, Kensuke
    Berlin, Jordan
    Saltz, Leonard B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Safety of trifluridine/tipiracil (FTD/TPI) in elderly patients with metastatic colorectal cancer.
    Mayer, Robert J.
    Hochster, Howard S.
    Cohen, Steven J.
    Winkler, Robert
    Makris, Lukas
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345